SVKM’S NMIMS, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, V.L. Mehta Road, Vile Parle West, Mumbai-400056, India
Curr Neuropharmacol. 2020;18(11):1106-1125. doi: 10.2174/1570159X18666200528142429.
The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other form of dementia. However, due to the non-feasibility of such methods, to diagnose and conclude the conditions, medical practitioners use tests that examine a patient's mental ability.
Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The cause for most Alzheimer's cases still remains unknown except where genetic distinctions have been observed. Thus, a standard drug regimen ensues in every Alzheimer's patient, irrespective of the cause, which may not always be beneficial in halting or reversing the disease progression. To provide a better life to such patients by suppressing existing symptoms, early diagnosis, curative therapy, site-specific delivery of drugs, and application of hyphenated methods like artificial intelligence need to be brought into the main field of Alzheimer's therapeutics.
In this review, we have compiled existing hypotheses to explain the cause of the disease, and highlighted gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics and quantum dots as advancements in the existing strategies to manage Alzheimer's.
Biomarkers, brain-imaging, and theranostics, along with artificial intelligence, are understood to be the future of the management of Alzheimer's.
诊断阿尔茨海默病的唯一确凿方法是对患者的脑组织进行尸检,以确定其是否患有阿尔茨海默病或任何其他形式的痴呆。然而,由于这些方法不可行,因此医疗从业者使用检查患者智力的测试来进行诊断和结论。
早期准确诊断是启动治疗的当务之急。除了观察到遗传差异外,大多数阿尔茨海默病病例的病因仍然未知。因此,无论病因如何,每个阿尔茨海默病患者都会采用标准的药物治疗方案,这并不总是有利于阻止或逆转疾病进展。为了通过抑制现有症状、早期诊断、治疗性疗法、药物的靶向递送来为这些患者提供更好的生活,需要将人工智能等杂交方法引入阿尔茨海默病治疗的主要领域。
在这篇综述中,我们汇编了现有的假设来解释疾病的原因,并强调了基因治疗、免疫疗法、肽模拟物、金属螯合剂、益生菌和量子点作为现有管理阿尔茨海默病策略的进展。
生物标志物、脑成像和治疗诊断学,以及人工智能,被认为是阿尔茨海默病管理的未来。